Icodextrin Metabolites in Peritoneal Dialysis

Holmes C.J. Glucotoxicity in peritoneal dialysis—solutions for the solution! Adv Chronic Kidney Dis 2007; 14: 269–78.

Heimbürger O. Peritoneal physiology. In: Pereira B.J.G. , Sayegh M.H. , Blake P. , eds. Chronic Kidney Disease, Dialysis, & Transplantation: Companion to Brenner & Rector's the Kidney. 2nd ed. Philadelphia: Elsevier Saunders; 2005: 491–513.

Krediet R.T. Osmotic agents in automated peritoneal dialysis solutions. Contrib Nephrol 1999; 129: 177–86.

Heimburger O. , Lindholm B. New solutions for peritoneal dialysis. In: Falkenhagen D. , Klinkmann H. , Piskin E. , eds. Blood–Material Interaction. A Basic Guide from Polymer Science to Clinical Application. Glasgow: International Faculty for Artificial Organs; 1998: 129–36.

Rippe B. , Levin L. Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 2000; 57: 2546–56.

Ho-dac-Pannekeet M.M. , Schouten N. , Langendijk M.J. , Hiralall J.K. , de Waart D.R. , Struijk D.G. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50: 979–86.

Pecoits-Filho R. , Mujais S. , Lindholm B. Future of icodextrin as an osmotic agent in peritoneal dialysis. Kidney Int Suppl 2002; 81: S80–7.

Davies S.J. , Brown E.A. , Frandsen N.E. , Rodrigues A.S. , Rodriguez-Carmona A. , Vychytil A. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609–15.

Alsop R.M. History, chemical and pharmaceutical development of icodextrin. Perit Dial Int 1994; 14(Suppl 2): S5–12.

Moberly J.B. , Mujais S. , Gehr T. , Hamburger R. , Sprague S. , Kucharski A. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl 2002; 81: S23–33.

Mujais S. , Vonesh E. Profiling of peritoneal ultrafiltration. Kidney Int Suppl 2002; 81: S17–22.

Finkelstein F. , Healy H. , Abu-Alfa A. , Ahmad S. , Brown F. , Gehr T. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16: 546–54.

Peers E. , Gokal R. Icodextrin: overview of clinical experience. Perit Dial Int 1997; 17: 22–6.

Gokal R. Newer peritoneal dialysis solutions. Adv Ren Replace Ther 2000; 7: 302–9.

Shockley T.R. , Martis L. , Tranaeus A.P. New solutions for peritoneal dialysis in adult and pediatric patients. Perit Dial Int 1999; 19(Suppl 2): S429–34.

Krediet R.T. The physiology of peritoneal solute transport and ultrafiltration. In: Gokal R. , Khanna R. , Krediet R.T. , Nolph K.D. , eds. Textbook of Peritoneal Dialysis. 2nd ed. Amsterdam: Kluwer Academic Publishers; 2000: 135–72.

Wang T. , Lindholm B. Peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3): S89–95.

Krishnan M. , Tam P. , Wu G. , Breborowicz A. , Oreopoulos D.G. Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes? Int Urol Nephrol 2005; 37: 409–18.

Frampton J. , Plosker G. Icodextrin: a review of its use in peritoneal dialysis. Drugs 2003; 63: 2079–105.

Davies D.S. Kinetics of icodextrin. Perit Dial Int 1994; 14(Suppl 2): S45–50.

Asghar R.B. , Diskin A.M. , Spanel P. , Smith D. , Davies S.J. Influence of convection on the diffusive transport and sieving of water and small solutes across the peritoneal membrane. J Am Soc Nephrol 2005; 16: 437–43.

Mistry C.D. , Gokal R. , Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46: 496–503.

Mistry C.D. , Mallick N.P. , Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2: 178–82.

Garcia-Lopez E. , Anderstam B. , Heimburger O. , Amici G. , Werynski A. , Lindholm B. Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients. Perit Dial Int 2005; 25: 181–91.

Wang R. , Moberly J.B. , Martis L. , Shockley T.R. , Mongoven J.W. , Patel H. . A rapid assay for icodextrin determination in plasma and dialysate. Adv Perit Dial 2002; 18: 91–5.

Garcia-Lopez E. , Pawlaczyk K. , Anderstam B. , Qureshi A.R. , Kuzlan-Pawlaczyk M. , Heimburger O. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis. Perit Dial Int 2007; 27: 415–23.

Mistry C.D. , Gokal R. Icodextrin in peritoneal dialysis: early development and clinical use. Perit Dial Int 1994; 14(Suppl 2): S13–21.

Burke R.A. , Hvizd M.G. , Shockley T.R. Direct determination of polyglucose metabolites in plasma using anion-exchange chromatography with pulsed amperometric detection. J Chromatogr B Biomed Sci Appl 1997; 693: 353–7.

Anderstam B. , Garcia-Lopez E. , Heimburger O. , Lindholm B. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid. Perit Dial Int 2003; 23: 146–50.

Davies S.J. , Garcia-Lopez E. , Woodrow G. , Donovan K. , Plum J. , Williams P. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008; 23: 2982–8.

Garcia-Lopez E. , Werynski A. , Heimburger O. , Filho J.C. , Lindholm B. , Anderstam B. Rate of synthetic oligosaccharide degradation as a novel measure of amylase activity in peritoneal dialysis patients. Perit Dial Int 2008; 28: 296–304.

Plum J. , Gentile S. , Verger C. , Brunkhorst R. , Bahner U. , Faller B. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39: 862–71.

Wolfson M. , Piraino B. , Hamburger R.J. , Morton A.R. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40: 1055–65.

Ota K. , Akiba T. , Nakao T. , Nakayama M. , Maeba T. , Park M.S. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients. Perit Dial Int 2003; 23: 356–61.

Rodriguez-Carmona A. , Perez Fontan M. , Garcia Lopez E. , Garcia Falcon T. , Diaz Cambre H. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007; 27: 260–6.

Posthuma N. , ter Wee P.M. , Donker A.J. , Oe P.L. , Peers E.M. , Verbrugh H.A. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int 2000; 20(Suppl 2): S106–13.

de Waart D.R. , Zweers M.M. , Struijk D.G. , Krediet R.T. Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality. Perit Dial Int 2001; 21: 269–74.

Flessner M.F. , Lofthouse J. Of mice and men: species and age differences in dialysis with icodextrin [Abstract]. J Am Soc Nephrol 1999; 10: 226A.

de Boer A.W. , Schroeder C.H. , van Vliet R. , Willems J.L. , Monnens L.A. Clinical experience with icodextrin in children: ultrafiltration profiles and metabolism. Pediatr Nephrol 2000; 15: 21–4.

Gobin J. , Fernando S. , Santacroce S. , Finkelstein F.O. The utility of two daytime icodextrin exchanges to reduce dextrose exposure in automated peritoneal dialysis patients: a pilot study of nine patients. Blood Purif 2008; 26: 279–83.

García-López E. Icodextrin metabolism in peritoneal dialysis: clinical and experimental studies [Thesis]. ISBN 978-91-7357-352-8. Stockholm: Karolinska Institutet; 2007.

Grzegorzewska A.E. , Antczak-Jedrzejczak D. , Mariak I. Polyglucose dialysis solution influences serum activity of amylase and of lipase differently. Adv Perit Dial 2000; 16: 113–18.

Mistry C.D. , Gokal R. Single daily overnight (12-h dwell) use of 7.5% glucose polymer (Mw 18700; Mn 7300) +0.35% glucose solution: a 3-month study. Nephrol Dial Transplant 1993; 8: 443–7.

Schoenicke G. , Grabensee B. , Plum J. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 2002; 17: 1988–92.

Wang R. , Leesch V. , Turner P. , Moberly J.B. , Martis L. Kinetic analysis of icodextrin interference with serum amylase assays. Adv Perit Dial 2002; 18: 96–9.

Posthuma N. , ter Wee P.M. , Donker A.J. , Oe P.L. , van Dorp W. , Peers E.M. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Perit Dial Int 1997; 17: 602–7.

Van Handel E. Trehalase and maltase in the serum of vertebrates. Comp Biochem Physiol 1968; 26: 561–6.

Weser E. , Sleisenger M.H. Metabolism of circulating disaccharides in man and the rat. J Clin Invest 1967; 46: 499–505.

Young J.M. , Weser E. The metabolism of circulating maltose in man. J Clin Invest 1971; 50: 986–91.

Gokal R. , Moberly J. , Lindholm B. , Mujais S. Metabolic and laboratory effects of icodextrin. Kidney Int Suppl 2002; 81: S62–71.

Martikainen T. , Teppo A.M. , Gronhagen-Riska C. , Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005; 23: 303–10.

Davies S.J. , Woodrow G. , Donovan K. , Plum J. , Williams P. , Johansson A.C. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338–44.